Track market-moving stories before they get noisy

, /PRNewswire/ -- Leading private markets investment management firm Hamilton Lane (Nasdaq: HLNE) announced that its Board of Directors elected Michael Schmertzler as a new independent director, effective July 22, 2026. Schmertzler's appointment constitutes the fifth independent director to be named to the Board, serving alongside the firm's three executive directors.

Hartley Rogers, Executive Co-Chairman at Hamilton Lane and Chairman of the HLNE Board, commented: "Michael is a highly accomplished executive who will be a strong addition to the Board. As the global investment landscape has become increasingly complex, his deep business, governance, technology and financial services experience across both private and public sectors will bring a valuable perspective to our Board and firm."

Erik Hirsch, Co-Chief Executive Officer and Board Member at Hamilton Lane, commented: "As our platform continues to scale, we are delighted to welcome Michael to the Board. We believe his strategic perspective and industry expertise will further enhance the Board's capabilities and help position Hamilton Lane to remain at the forefront of innovation, growth and value creation across the private markets."

Schmertzler brings extensive investment, corporate finance and governance experience to the HLNE Board. Since 1998, he has served as a Lecturer and Adjunct Professor at Yale University in the Department of Economics and School of Management and during that time was also a Visiting Professor at Yale-NUS College Singapore.

He currently serves as Chairman and director of PTC Therapeutics, Inc. (Nasdaq: PTCT), a publicly traded biotechnology company focused on treatments for rare genetic disorders. He is also Chairman and a director of Berryville Holdings, which develops attribution and protection systems for the defense and intelligence community and of Dispel, LLC, a provider of communication networks for operational technology. In addition, he serves as Executive Chairman of SHY Therapeutics and as a director of AgNovos, both biotechnology companies. He is also a Charter Trustee of Phillips Academy Andover.

Schmertzler's prior investment and corporate finance experience includes serving as a post-bankruptcy independent director of Lehman Commercial Paper, Inc. (2012-2020).  Earlier in his career, he was a Managing Director at Credit Suisse First Boston Equity Partners, L.P., serving in various roles including as Chair of the Investment Committee (1997-2014). Prior to that, he served as a Managing Director at Morgan Stanley and held senior roles including as President of Morgan Stanley Leveraged Capital Funds.

"I am delighted to join Hamilton Lane's Board and look forward to contributing from my experience and collaborating with its leadership as they grow its global platform and capabilities," said Schmertzler.

He received a B.A. from Yale College in Molecular Biophysics and Biochemistry, History, and City Planning, and an M.B.A. from Harvard Business School.

About Hamilton Lane

Hamilton Lane (Nasdaq: HLNE) is one of the largest private markets investment firms globally, providing innovative solutions to institutional and private wealth investors around the world. Dedicated exclusively to private markets investing for more than 30 years, the firm currently employs approximately 785 professionals operating in offices throughout North America, Europe, Asia Pacific and the Middle East. Hamilton Lane has $1 trillion in assets under management and supervision, composed of $141.8 billion in discretionary assets and $905.3 billion in non-discretionary assets, as of March 31, 2026. Hamilton Lane specializes in building flexible investment programs that provide clients access to the full spectrum of private markets strategies, sectors and geographies. For more information, please visit our website or follow Hamilton Lane on LinkedIn.

SOURCE Hamilton Lane

, /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its second quarter 2026 financial results and provide an update on the company's business and outlook on Thursday, July 30, 2026, at 4:30 p.m. ET.

To access the live webcast, please visit the "Events & Presentations" page within the Investors section of the PTC website. A replay of the webcast will be available on the PTC website for 30 days following the event. To participate via phone, please register in advance here to receive dial-in details.

About PTC Therapeutics, Inc. 
PTC is a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. The company's strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders. To learn more about PTC, please visit www.ptcbio.com and follow us on LinkedIn, X, Facebook and Instagram.

For more information, please contact:

Investors:
Ellen Cavaleri
+1 (615) 618-8228
[email protected]

Media:
Jeanine Clemente
+1 (908) 912-9406
[email protected]

SOURCE PTC Therapeutics, Inc.

Key Takeaways PTCT's Sephience posted revenues of $125M in Q1 2026 with 36% sequential growth after its 2025 launch.PTCT markets multiple rare disease therapies and earns Evrysdi royalty revenues.PTCT advanced votoplam and vatiquinone, with phase III progress and a planned FDA-backed study. PTC Therapeutics (PTCT - Free Report) has built a diversified global commercial portfolio across multiple rare disease indications, providing a strong foundation for sustainable revenue growth.

Sephience: PTCT’s Major Growth DriverPTC’s growth largely depends on Sephience (sepiapterin), its approved therapy for phenylketonuria, which has consistently exceeded market expectations since its 2025 launch. The drug is approved in the United States, Europe, Japan and other international markets. During the first quarter of 2026, Sephience generated $125 million in product revenues, representing 36% sequential growth, as adoption strengthened across both the U.S. and international markets.

Management expects the therapy to be available in nearly 30 countries by the end of 2026, significantly expanding its commercial opportunity and reinforcing its position as PTC’s  primary commercial growth driver. Commercial momentum remains robust, with 1,244 patients receiving therapy worldwide as of March 31, 2026, while the United States continued to add approximately 140 new patient start forms per month.

Year to date, PTCT shares have risen 17.9% compared with the industry’s 6.3% growth.

Image Source: Zacks Investment Research

Other Marketed Drugs in PTCT’s Commercial PortfolioBeyond Sephience, PTC also benefits from a diversified portfolio of marketed rare disease therapies that provide stable revenues to support future innovation.

The company maintains an established Duchenne muscular dystrophy (DMD) franchise through Emflaza, approved in the United States for patients aged two years and older, and Translarna, which continues to generate meaningful revenues in select international markets for patients with nonsense mutation DMD despite ongoing regulatory challenges in Europe.

PTC has strengthened its gene therapy franchise with Upstaza/Kebilidi, an approved treatment for aromatic L-amino acid decarboxylase deficiency that is commercialized across Europe, the United Kingdom and the United States.

Under its licensing agreement with Ionis Pharmaceuticals (IONS - Free Report) , PTC holds exclusive commercialization rights for Tegsedi and Waylivra in Latin America and the Caribbean. Tegsedi is approved for hereditary transthyretin amyloidosis with polyneuropathy, while Waylivra is approved for rare lipid disorders, including familial chylomicronemia syndrome and familial partial lipodystrophy.

The company also receives royalty revenues from Evrysdi, Roche's (RHHBY - Free Report) globally marketed spinal muscular atrophy therapy, which is approved in more than 100 countries.

PTCT’s Meaningful Pipeline ExpansionBeyond its marketed therapies, PTC has a promising late-stage pipeline focused on rare neurological disorders.

Votoplam, an oral splicing therapy for Huntington's disease, reported positive 24-month phase II extension data in April 2026, demonstrating dose-dependent slowing of disease progression along with a favorable safety profile. These data support the ongoing global phase III INVEST-HD study being led by Novartis (NVS - Free Report) . The phase III study initiation triggered a $50 million milestone payment from Novartis to PTC in the second quarter of 2026, underscoring the program's strategic and commercial potential.

If successful, votoplam could become the first approved oral therapy capable of modifying Huntington's disease progression, representing a significant commercial opportunity in a disease with high unmet medical need.

Another important value driver is vatiquinone, which is progressing toward a registration-enabling study in Friedreich's ataxia, with study initiation planned for the third quarter of 2026 following constructive FDA discussions.

PTCT's Zacks Rank & EstimatesPTC currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 60 days, estimates for PTCT’s bottom line have improved from a loss per share of $1.40 to earnings of 78 cents per share. Over the aforementioned period, EPS estimates for 2027 have risen from $1.20 to $2.11.

Key Takeaways CPRX reported phase I data supporting Agamree's potential label expansion beyond approved DMD use. CPRX said Agamree matched Emflaza's activity while showing fewer immunosuppressive biomarker effects. CPRX found no meaningful immunosuppression at lower therapeutic doses, supporting future studies. Catalyst Pharmaceuticals (CPRX - Free Report) has reported positive top-line results from an early-stage study evaluating Agamree (vamorolone) to explore additional indications beyond its currently approved use in Duchenne muscular dystrophy (DMD) patients aged two years and older.

The phase I study assessed Agamree's glucocorticoid activity, anti-inflammatory effects and immunosuppressive profile in healthy adults compared with PTC Therapeutics' (PTCT - Free Report) Emflaza (deflazacort). The findings suggest that Agamree may deliver corticosteroid benefits without the clinically meaningful immunosuppression associated with conventional corticosteroids at approved doses, potentially opening the door to additional chronic inflammatory rare disease indications. Lower immunosuppressive activity may reduce the risk of infection and immune-related adverse effects commonly associated with chronic corticosteroid use.

Under a 2023 licensing agreement with Santhera, Catalyst Pharmaceuticals holds exclusive commercialization rights for Agamree in North America for DMD as well as any future indications, while Santhera retains the right of first negotiation for new indication rights outside North America. The agreement also entitles Santhera to sales-based milestone payments and royalties across all commercialized indications, making any label expansion a potentially important value driver.

The phase I study consisted of two parts involving healthy adult volunteers. Part A was a randomized crossover study designed to assess equipotency between Agamree and PTCT's Emflaza, helping evaluate the clinical scenario in which a patient might experience differential cortisol effects when switching from Emflaza to Agamree. Part B evaluated multiple ascending doses of Agamree to determine whether clinically meaningful immunosuppression emerges at higher doses.

Year to date, Catalyst Pharmaceuticals shares have gained 34.7% compared with the industry’s 6.3% growth.

Image Source: Zacks Investment Research

CPRX’s Phase I Agamree Study Findings in DetailPart A of the phase I study enrolled 24 healthy adults who received either a single 300 mg dose of Agamree or a 0.9 mg/kg dose of Emflaza. Both therapies demonstrated expected on-target glucocorticoid receptor activity, producing comparable cortisol suppression, leukocyte redistribution and functional immune biomarker changes. Their onset of activity was also similar, occurring roughly two to four hours after dosing.

Despite comparable glucocorticoid activity, Agamree produced less pronounced immunosuppressive biomarker effects than PTC Therapeutics' Emflaza. Per management, the comparable cortisol suppression supports the currently approved Agamree dosing and suggests that patients switching from Emflaza to Agamree are unlikely to require additional dosing adjustments.

Part B enrolled 36 healthy volunteers who received Agamree at daily doses of 9, 27 or 40 mg/kg for seven days. Clinically relevant immunosuppressive effects were observed only at the highest Agamree dose, which exceeds currently approved and previously studied clinical dosing levels. No meaningful immunosuppressive effects were detected at the lower 9 mg/kg or 27 mg/kg doses. However, immune suppression became more pronounced with repeated dosing at 40 mg/kg and persisted after treatment ended.

Collectively, the data indicate that Agamree maintains glucocorticoid and anti-inflammatory activity while avoiding clinically meaningful immunosuppression at therapeutic doses. These findings strengthen Catalyst Pharmaceuticals' efforts to broaden Agamree's label into additional chronic inflammatory rare diseases while further differentiating the therapy from PTC Therapeutics’ Emflaza and other traditional corticosteroids.

CPRX is Set to be Acquired by Angelini Pharma in $4.1B DealCatalyst Pharmaceuticals’ pipeline progress comes as the company moves toward its planned acquisition by Angelini Pharma in a transaction valued at approximately $4.1 billion. Under the definitive agreement announced in May 2026, Angelini Pharma will acquire CPRX for $31.50 per share in cash, representing a 21% premium to the latter’s unaffected closing share price on April 22, 2026, the last trading day before market signs that the transaction had become public information. The deal has received unanimous approval from the boards of both companies and is expected to close during the third quarter of 2026, subject to shareholder and regulatory approvals.

The acquisition marks Angelini Pharma's entry into the U.S. market while expanding its rare disease and brain health portfolio. Following completion, Angelini plans to integrate Catalyst Pharmaceuticals’ commercial infrastructure and rare disease portfolio, including Agamree, Firdapse (approved for Lambert-Eaton myasthenic syndrome) and Fycompa (approved for epilepsy), with its existing neuroscience expertise. For CPRX, the transaction provides shareholders with immediate cash value while positioning its therapies for broader global commercialization and continued investment in rare disease development.

CPRX’s Zacks Rank & Stocks to ConsiderCatalyst Pharmaceuticals currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the biotech sector are Liquidia Corporation (LQDA - Free Report) and Immunocore (IMCR - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 60 days, estimates for Liquidia’s 2026 EPS have increased from $1.50 to $3.02. Over the same period, EPS estimates for 2027 have also risen from $2.91 to $4.92. LQDA shares have surged 130% year to date.

Liquidia’searnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.

The estimate for Immunocore’s 2026 EPS is currently pegged at 6 cents, while the same for its 2027 EPS is currently pegged at 87 cents. IMCR shares have lost 8.9% year to date.

Immunocore’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, with the average surprise being 46.66%.

PTC Therapeutics (PTCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

– Refinancing transaction with proceeds to be utilized to repurchase or repay the 2026 convertible notes prior to or at maturity –

– Offering made at 0% interest with conversion price of $107.48, a 40% premium over the closing price on June 15, 2026 –

, /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced the pricing of $500.0 million aggregate principal amount of 0% Convertible Senior Notes due 2031 (the "Notes") in a private placement (the "Offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). PTC also granted the initial purchasers an option to purchase, within the 13-day period beginning on, and including, the date on which the Notes are first issued, up to an additional $50.0 million aggregate principal amount of Notes from PTC. The sale of the Notes is expected to close on June 18, 2026, subject to the satisfaction of customary closing conditions.

The Notes will be general senior unsecured obligations of PTC, and will not bear regular interest and the principal amount of the Notes will not accrete. The Notes will mature on June 15, 2031, unless earlier converted, repurchased or redeemed.

PTC estimates that the net proceeds from the Offering will be approximately $486.8 million (or approximately $535.5 million if the initial purchasers exercise their option to purchase additional Notes in full), after deducting the initial purchasers' discounts and commissions and estimated offering expenses payable by PTC.

PTC expects to use approximately $328.8 million of the net proceeds from the Offering to repurchase for cash $222.0 million in aggregate principal amount of its 1.5% Convertible Senior Notes due 2026 (the "2026 Notes") pursuant to the concurrent note repurchase transactions described below. Given the dynamics of the Offering, PTC will not use any proceeds of the Offering to repurchase, concurrently with the Offering, shares of its common stock sold short by initial investors in the Offering. The remaining net proceeds from the Offering will be used for general corporate purposes, which may include additional repurchases of the 2026 Notes from time to time following the Offering and the repayment or retirement of any remaining 2026 Notes at maturity.

Prior to the close of business on the business day immediately preceding March 15, 2031, holders will have the right to convert their Notes only upon the satisfaction of specified conditions and during certain periods. On or after March 15, 2031 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or any portion of their Notes at any time. Upon conversion, PTC will pay or deliver, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at its election.

The conversion rate for the Notes will initially be 9.3042 shares of PTC's common stock per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $107.48 per share of PTC's common stock). The initial conversion price represents a premium of approximately 40% over the closing price of $76.77 per share of PTC's common stock on the Nasdaq Global Select Market on June 15, 2026.

PTC may not redeem the Notes prior to June 20, 2029. On or after June 20, 2029, PTC may redeem for cash all or any portion of the Notes, at its option, if the last reported sale price of PTC's common stock has been at least 130% of the conversion price for the Notes then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which PTC provides written notice of redemption at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid special interest, if any, to, but excluding, the redemption date. No sinking fund is provided for the Notes, which means PTC is not required to redeem or retire the Notes periodically.

If PTC undergoes a "fundamental change" (as defined in the indenture that will govern the Notes), then, subject to certain conditions and limited exceptions, holders may require PTC to repurchase for cash all or any portion of their Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid special interest, if any, to, but excluding, the fundamental change repurchase date. In addition, following certain corporate events that occur prior to the maturity date or if PTC delivers a notice of redemption, PTC will, in certain circumstances, increase the conversion rate for a holder who elects to convert its Notes in connection with such a corporate event or notice of redemption, as the case may be.

Concurrently with the pricing of the Notes in the Offering, PTC entered into private negotiated transactions with certain holders of the 2026 Notes to repurchase for a total repurchase cost (including accrued and unpaid interest) of approximately $328.8 million in cash $222.0 million in aggregate principal amount of the 2026 Notes on terms negotiated with each holder. This press release is not a notice of redemption or an offer to repurchase the 2026 Notes, and the Offering of the Notes is not contingent upon the repurchase of any of the 2026 Notes.

In connection with any repurchase of the 2026 Notes, PTC expects that holders of the 2026 Notes who agreed to have their 2026 Notes repurchased may enter into or unwind various derivatives with respect to PTC's common stock and/or purchase shares of PTC's common stock concurrently with or shortly after the pricing of the 2026 Notes. In particular, PTC expects that certain holders of the 2026 Notes employ a convertible arbitrage strategy with respect to the 2026 Notes and have a short position with respect to PTC's common stock that they will close out through purchases of PTC's common stock and/or the unwinding of various derivatives with respect to PTC's common stock, as the case may be, in connection with PTC's repurchase of the 2026 Notes. This activity could increase (or reduce the size of any decrease in) the market price of PTC's common stock, which may also affect the trading price of the Notes at that time. This activity may have affected the market price of PTC's common stock prior to, concurrently with or shortly after the pricing of the Notes, and could result in a higher effective conversion price of the Notes. PTC cannot predict the magnitude of such market activity or the overall effect it will have on the price of the Notes or PTC's common stock.

The Notes were only offered by means of a private offering memorandum. The offer and sale of the Notes and any shares of PTC's common stock issuable upon conversion of the Notes have not been, and will not be, registered under the Securities Act or any other securities laws, and the Notes and any such shares cannot be offered or sold except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, the Notes or any shares of PTC's common stock issuable upon conversion of the Notes, nor will there be any sale of the Notes or any such shares, in any state or other jurisdiction in which such offer, sale or solicitation would be unlawful. 

About PTC Therapeutics, Inc. 
PTC is a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. The company's strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders.

For more information please contact:

Investors:
Ellen Cavaleri
+1 (615) 618-8228
[email protected]

Media:
Jeanine Clemente
+1 (908) 912-9406
[email protected]

Cautionary Note Regarding Forward-Looking Statements:

The press release contains information about future expectations, plans and prospects of PTC's management that constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995, including statements with respect to PTC's expectations to complete the Offering of the Notes, its use of proceeds from the Offering and the effect of the concurrent note repurchase. There can be no assurance that PTC will be able to complete the notes offering on the anticipated terms, or at all. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including, but not limited to, the terms of the Notes and the Offering, risks and uncertainties related to whether or not PTC will consummate the Offering, the impact of general economic, industry, market or political conditions and other factors that are discussed in PTC's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and other documents periodically filed with the Securities and Exchange Commission.

In addition, the statements in this press release represent PTC's expectations and beliefs as of the date of this press release. PTC anticipates that subsequent events and developments may cause these expectations and beliefs to change. However, while PTC may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing PTC's expectations or beliefs as of any date subsequent to the date of this press release.

SOURCE PTC Therapeutics, Inc.

Posted by Defense World Staff on Apr 7th, 2026

PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) EVP Lee Scott Golden sold 829 shares of PTC Therapeutics stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $67.99, for a total value of $56,363.71. Following the completion of the sale, the executive vice president directly owned 79,115 shares in the company, valued at $5,379,028.85. This represents a 1.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Lee Scott Golden also recently made the following trade(s):

On Thursday, March 5th, Lee Scott Golden sold 10,000 shares of PTC Therapeutics stock. The stock was sold at an average price of $63.38, for a total value of $633,800.00. On Wednesday, February 18th, Lee Scott Golden sold 2,484 shares of PTC Therapeutics stock. The stock was sold at an average price of $69.36, for a total value of $172,290.24. On Thursday, January 8th, Lee Scott Golden sold 866 shares of PTC Therapeutics stock. The shares were sold at an average price of $76.45, for a total value of $66,205.70. On Wednesday, January 7th, Lee Scott Golden sold 642 shares of PTC Therapeutics stock. The shares were sold at an average price of $77.48, for a total value of $49,742.16. On Tuesday, January 6th, Lee Scott Golden sold 1,340 shares of PTC Therapeutics stock. The shares were sold at an average price of $76.95, for a total value of $103,113.00. PTC Therapeutics Stock Up 1.7% NASDAQ:PTCT opened at $68.90 on Tuesday. PTC Therapeutics, Inc. has a 52 week low of $35.95 and a 52 week high of $87.50. The company has a market capitalization of $5.70 billion, a P/E ratio of 8.90 and a beta of 0.55. The stock’s fifty day moving average is $68.91 and its two-hundred day moving average is $71.17.

PTC Therapeutics (NASDAQ:PTCT – Get Free Report) last posted its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($1.46). PTC Therapeutics had a negative return on equity of 362.45% and a net margin of 39.44%.The firm had revenue of $164.68 million for the quarter, compared to analyst estimates of $281.45 million. During the same period in the previous year, the company posted ($0.85) EPS. PTC Therapeutics’s revenue was down 22.7% on a year-over-year basis. Sell-side analysts anticipate that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current fiscal year.

Analysts Set New Price Targets PTCT has been the subject of several analyst reports. Wall Street Zen cut PTC Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, February 21st. TD Cowen reissued a “hold” rating on shares of PTC Therapeutics in a research report on Thursday, January 29th. Bank of America decreased their target price on PTC Therapeutics from $97.00 to $93.00 and set a “buy” rating for the company in a research report on Friday, February 20th. Wells Fargo & Company decreased their target price on PTC Therapeutics from $93.00 to $86.00 and set an “overweight” rating for the company in a research report on Friday, February 20th. Finally, Jefferies Financial Group cut PTC Therapeutics from a “buy” rating to a “hold” rating and decreased their target price for the company from $91.00 to $76.00 in a research report on Monday, March 30th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, PTC Therapeutics has an average rating of “Moderate Buy” and an average target price of $82.71.

Check Out Our Latest Analysis on PTCT

Hedge Funds Weigh In On PTC Therapeutics A number of large investors have recently modified their holdings of PTCT. Jefferies Financial Group Inc. purchased a new stake in PTC Therapeutics during the third quarter worth $97,252,000. Janus Henderson Group PLC increased its position in shares of PTC Therapeutics by 28.6% in the fourth quarter. Janus Henderson Group PLC now owns 4,851,332 shares of the biopharmaceutical company’s stock valued at $368,587,000 after buying an additional 1,077,776 shares in the last quarter. State Street Corp raised its stake in shares of PTC Therapeutics by 34.2% during the 4th quarter. State Street Corp now owns 4,206,126 shares of the biopharmaceutical company’s stock worth $319,497,000 after buying an additional 1,071,343 shares during the last quarter. Toronto Dominion Bank raised its stake in shares of PTC Therapeutics by 27.5% during the 4th quarter. Toronto Dominion Bank now owns 4,138,215 shares of the biopharmaceutical company’s stock worth $314,339,000 after buying an additional 891,690 shares during the last quarter. Finally, BNP Paribas Financial Markets grew its stake in PTC Therapeutics by 4,013.1% in the 4th quarter. BNP Paribas Financial Markets now owns 828,662 shares of the biopharmaceutical company’s stock valued at $62,945,000 after acquiring an additional 808,515 shares during the last quarter.

PTC Therapeutics Company Profile (Get Free Report)

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.

Read More Five stocks we like better than PTC Therapeutics

Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINESound Group (NASDAQ:SOGP) Director Ming Zhang Sells 1,001 Shares of Stock

NEXT HEADLINE »Pelthos Therapeutics (NYSEAMERICAN:PTHS) Director Richard Malamut Sells 590 Shares of Stock

, /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 13, 2026, the company approved non-statutory stock options to purchase an aggregate of 1,155 shares of its common stock and 925 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to a new non-executive employee. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hire's employment compensation.

The inducement grant was approved by PTC's Compensation Committee on April 13, 2026, and is being made as an inducement material to the employee's acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).

All stock option awards have an exercise price of $70.42 per share, the closing price of PTC's common stock on April 13, 2026, the date of the grant. The stock options each have a 10-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the employee's new hire date and 6.25% of the original number of shares vesting at the end of each subsequent three-month period thereafter until fully vested, subject to the employee's continued service with the company through the vesting dates. The RSUs each will vest over four years, with 25% of the original number of shares vesting on each annual anniversary of the employee's new hire date until fully vested, subject to the employee's continued service with the company through the vesting dates.

ABOUT PTC THERAPEUTICS, INC.
PTC is a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. The company's strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders. To learn more about PTC, please visit www.ptcbio.com and follow us on LinkedIn, X, Instagram and Facebook.

For more information, please contact:

Investors:
Ellen Cavaleri
+1 (615) 618-8228
[email protected]

Media:
Jeanine Clemente
+1 (908) 912-9406
[email protected]

SOURCE PTC Therapeutics, Inc.

Posted by Defense World Staff on Apr 26th, 2026

Abacus FCF Advisors LLC bought a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 75,757 shares of the biopharmaceutical company’s stock, valued at approximately $5,755,000. Abacus FCF Advisors LLC owned about 0.09% of PTC Therapeutics at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC increased its position in PTC Therapeutics by 101.3% during the third quarter. Smartleaf Asset Management LLC now owns 469 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 236 shares during the last quarter. Optiver Holding B.V. boosted its holdings in shares of PTC Therapeutics by 96.5% in the 3rd quarter. Optiver Holding B.V. now owns 507 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 249 shares during the last quarter. Comerica Bank boosted its holdings in shares of PTC Therapeutics by 868.5% in the 3rd quarter. Comerica Bank now owns 523 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 469 shares during the last quarter. Salomon & Ludwin LLC acquired a new stake in shares of PTC Therapeutics during the 4th quarter worth $41,000. Finally, First Horizon Corp purchased a new position in shares of PTC Therapeutics in the 4th quarter worth $53,000.

Wall Street Analysts Forecast Growth A number of analysts have recently issued reports on the company. Jefferies Financial Group cut PTC Therapeutics from a “buy” rating to a “hold” rating and decreased their target price for the stock from $91.00 to $76.00 in a report on Monday, March 30th. Bank of America cut their price target on shares of PTC Therapeutics from $97.00 to $93.00 and set a “buy” rating on the stock in a report on Friday, February 20th. Morgan Stanley upped their price target on shares of PTC Therapeutics from $90.00 to $92.00 and gave the stock an “overweight” rating in a research report on Monday, February 23rd. Weiss Ratings reissued a “hold (c)” rating on shares of PTC Therapeutics in a research report on Monday, December 29th. Finally, Raymond James Financial initiated coverage on PTC Therapeutics in a research note on Friday, April 10th. They set an “outperform” rating and a $108.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $84.40.

Read Our Latest Research Report on PTCT

PTC Therapeutics Price Performance PTCT opened at $68.23 on Friday. The stock has a market capitalization of $5.66 billion, a PE ratio of 8.82 and a beta of 0.55. The firm’s fifty day moving average price is $68.14 and its 200 day moving average price is $72.02. PTC Therapeutics, Inc. has a 12-month low of $35.95 and a 12-month high of $87.50.

PTC Therapeutics (NASDAQ:PTCT – Get Free Report) last posted its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($1.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($1.46). The company had revenue of $164.68 million for the quarter, compared to the consensus estimate of $281.45 million. PTC Therapeutics had a net margin of 39.44% and a negative return on equity of 362.45%. The company’s revenue was down 22.7% compared to the same quarter last year. During the same quarter last year, the company earned ($0.85) earnings per share. On average, equities research analysts forecast that PTC Therapeutics, Inc. will post -0.76 earnings per share for the current fiscal year.

Insiders Place Their Bets In related news, insider Neil Gregory Almstead sold 52,003 shares of the business’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $69.04, for a total transaction of $3,590,287.12. Following the completion of the sale, the insider owned 60,137 shares of the company’s stock, valued at $4,151,858.48. This represents a 46.37% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Lee Scott Golden sold 10,000 shares of the stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $63.38, for a total transaction of $633,800.00. Following the sale, the executive vice president owned 79,944 shares in the company, valued at approximately $5,066,850.72. This trade represents a 11.12% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 126,492 shares of company stock worth $8,634,621. Corporate insiders own 5.50% of the company’s stock.

PTC Therapeutics Company Profile (Free Report)

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.

See Also Five stocks we like better than PTC Therapeutics

Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEMcDonald’s Corporation $MCD Stock Holdings Increased by Advisors Capital Management LLC

NEXT HEADLINE »Advisors Capital Management LLC Reduces Position in Accenture PLC $ACN

- Dose-dependent benefit on cUHDRS in Stage 2 participants compared to matched natural history cohort, with 52% slowing at 10 mg dose -

- Continued evidence of favorable safety profile - 

- Novartis initiated global Phase 3 INVEST-HD study of votoplam -

- PTC will host a conference call to discuss results today, April 28, at 4:30 pm ET - 

, /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today reported positive topline results from the 24-month interim analysis of the PIVOT-HD long-term extension study, with favorable dose-dependent effects on disease progression for Stage 2 Huntington's disease (HD) patients following 24 months of votoplam treatment compared to an external natural history cohort. 

"These results give us confidence in the potential for votoplam to deliver long-term meaningful effect on slowing Huntington's disease progression," said Matthew B. Klein, M.D., Chief Executive Officer, PTC Therapeutics. "In particular, the evidence of dose-dependent slowing of progression on the cUHDRS disease rating scale in the Stage 2 study participants supports the Novartis-initiated Phase 3 INVEST-HD study. We look forward to continuing to review the data and aligning on potential regulatory interactions based on the results with our partner Novartis."

The PIVOT-HD study was a 12-month placebo-controlled study of two dose levels of votoplam in participants with Stage 2 and Stage 3 HD. The study met the primary endpoint of blood Huntingtin (HTT) protein lowering at 12 weeks, with persistent dose-dependent lowering at Month 12. PIVOT-HD participants then enrolled in the PIVOT-HD extension study in which those originally randomized to receive 5 mg or 10 mg of votoplam remained on those dose levels. Participants initially randomized to receive placebo were randomized to receive 5 mg or 10 mg. All participants and investigators remain blinded to initial PIVOT-HD treatment assignment. The objectives of the long-term extension study are to assess the safety and efficacy of long-term votoplam treatment. 

In the interim analysis following 24 months of votoplam treatment, there was evidence of dose-dependent benefit in slowing progression on the Composite Unified Huntington's Disease Rating Scale (cUHDRS) relative to a propensity weighted natural history cohort in Stage 2 participants, with 52% and 28% slowing for 10 mg and 5 mg participants, respectively. Signals of favorable treatment effects relative to natural history were recorded across the cUHDRS subscales for the 10 mg cohort. In addition, there were no treatment-related neurofilament light chain protein (NfL) increases and mean NfL levels remained below baseline at 24 months for both high and low dose cohorts – in contrast to the reported natural history that NfL levels increase over time in individuals with HD. In Stage 3 participants, potential signals of slowing of progression were observed at 24 months. Importantly, the safety data at Month 24 for both dose levels and both stages were consistent with the previously established evidence of favorable safety. 

Novartis announced their initiation of the global Phase 3 INVEST-HD study on their First Quarter Earnings Call earlier today. This placebo-controlled study will enroll approximately 770 individuals with early-stage HD who will be randomized 3:2 to receive votoplam 10 mg or placebo. The primary endpoint will be the change from baseline up to month 36 in the cUHDRS. The INVEST-HD study is sponsored and funded by Novartis. Novartis and PTC will continue to review the data and discuss potential next steps including regulatory interactions.

Conference Call and Webcast Details:
PTC will hold a conference call at 4:30 pm ET today to discuss this news. The webcast conference call can be accessed on the Investors section of the PTC website at https://ir.ptcbio.com/events-presentations. To participate via phone, please register in advance here to receive dial-in details. A replay of the call will be available approximately two hours after completion of the call and will be archived on the company's website for 30 days following the call.

About PIVOT-HD
PIVOT-HD was designed as a 12-month placebo-controlled trial to assess pharmacodynamic effect and safety of votoplam at two dose levels, 5 mg and 10 mg, relative to placebo. Initially, the study included only Stage 2 patients. A Stage 3 cohort of similar size was subsequently added to help identify the best study population for future studies. The primary endpoints of PIVOT-HD were total blood Huntingtin (HTT) lowering at 12 weeks and safety events. Secondary endpoints included 12-month blood HTT levels, and other blood-and central nervous system (CNS) biomarkers as well as changes in Composite Unified Huntington's Disease Rating Scale (cUHDRS).

Following 12 months, patients were eligible to enroll in a long-term extension study in which all subjects would receive votoplam. Those originally randomized to 5 mg and 10 mg would continue at that dose level; those initially randomized to placebo would be randomized 1:1 to 5 mg or 10 mg. All subjects and investigators remain blinded to initial treatment assignment.

About Votoplam
Votoplam (formerly PTC518) is a small molecule splicing modifier that acts via a unique mechanism to promote the inclusion of a novel pseudoexon containing a premature termination codon, thus triggering Huntingtin (HTT) mRNA degradation and subsequent reduction in HTT protein levels. Votoplam was discovered from PTC's validated splicing platform, following the successful discovery and development of Evrysdi® (risdiplam) for spinal muscular atrophy (SMA). Votoplam was partnered with Novartis in December 2024. Following the completion of the PIVOT-HD clinical trial, Novartis assumed responsibility for votoplam's development, manufacturing and commercialization.

About Huntington's Disease
Huntington's disease (HD) is a fatal, hereditary, genetic disorder of the central nervous system.1 It is caused by a defective gene. This gene produces a protein, called Huntingtin (HTT), which is involved in the functioning of the nerve cells in the brain (neurons). When the gene is defective, it produces an abnormal (or mutated) HTT protein that is toxic and causes neuron damage and neuron death.2  HD usually presents in people who are in their 30s or 40s. Symptoms can present earlier in life, and this is called Juvenile HD.2,3 There are also cases of infantile HD, when symptoms develop in children who are younger than 10 years old.2 While symptoms vary from person to person, the disease primarily affects the brain and results in abnormal movements, difficulties with speech, swallowing and walking, as well as a number of other symptoms including behavioral, cognitive and motor symptoms.4,5 While there are therapies approved for specific disease symptoms, currently, there is no cure for HD and there are no approved drugs that delay the onset or slow disease progression.

About PTC Therapeutics, Inc.
PTC is a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. The company's strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders. To learn more about PTC, please visit www.ptcbio.com and follow us on LinkedIn, X, Instagram and Facebook.

For More Information:

Investors:
Ellen Cavaleri
+1 (615) 618-6228
[email protected]

Media:
Jeanine Clemente
+1 (908) 912-9406
[email protected] 

Forward-Looking Statement:
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historic fact, are forward-looking statements, including statements with respect to the future expectations, plans and prospects for PTC, PTC's strategy, including with respect to the expected timing of clinical trials and studies, availability of data, regulatory submissions and responses, and other matters, future operations, future financial position, future revenues, projected costs; and the objectives of management. Other forward-looking statements may be identified by the words, "guidance", "plan," "anticipate," "believe," "estimate," "expect," "intend," "may," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions.

PTC's actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those related to: the outcome of pricing, coverage and reimbursement negotiations with third party payors for PTC's products or product candidates that PTC commercializes or may commercialize in the future; expectations with respect to PTC's license and collaboration agreement with Novartis Pharmaceuticals Corporation for votoplam for the treatment of Huntington's disease including its right to receive development, regulatory and sales milestones, profit sharing and royalty payments from Novartis, the design and expected timing of clinical trials and studies, the availability of data, and regulatory submissions and responses, including potential accelerated approval; significant business effects, including the effects of industry, market, economic, political or regulatory conditions; changes in tax and other laws, regulations, rates and policies; the eligible patient base and commercial potential of PTC's products and product candidates; PTC's scientific approach and general development progress; the sufficiency of PTC's cash resources and its ability to obtain adequate financing in the future for its foreseeable and unforeseeable operating expenses and capital expenditures; and the factors discussed in the "Risk Factors" section of PTC's most recent Annual Report on Form 10-K, as well as any updates to these risk factors filed from time to time in PTC's other filings with the SEC. You are urged to carefully consider all such factors.

As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that any product will receive or maintain regulatory approval in any territory or prove to be commercially successful.

The forward-looking statements contained herein represent PTC's views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this press release except as required by law.

References:

World Health Organization, 2020. 8A01.10 Huntington disease. Available at: https://icd.who.int/browse10/2019/en#/G10. Accessed October 2021. Gatto EM, González Rojas N, Persi G, et al. Clin Parkinsonism Rel Disord 2020;3:100056. Tabrizi SJ, Flower MD, Ross CA, et al. Nat Rev Neurol 2020;16(10):529–546. Roos RAC. Orphanet J Rare Dis 2010; 5:40. Kirkwood SC, Su JL, Conneally P, et al. Arch Neurol 2001;58(2):273–278. SOURCE PTC Therapeutics, Inc.

PTC Therapeutics, Inc. (PTCT) Discusses 24-Month Interim Results of PIVOT-HD Long-Term Extension Study of Votoplam in Huntington's Disease Transcript

, /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences:

Bank of America Securities Health Care Conference 2026
Tuesday, May 12 at 8:40 a.m. PDT / 11:40 a.m. EDT

RBC Capital Markets 2026 Global Healthcare Conference
Wednesday, May 20 at 10 a.m. EDT

Goldman Sachs 47th Annual Global Healthcare Conference
Tuesday, June 9 at 9:20 a.m. EDT

The presentations will be webcast live on the Events and Presentations page under the Investor section of PTC Therapeutics' website at https://ir.ptcbio.com/events-presentations and will be archived for 30 days following the presentation.

About PTC Therapeutics, Inc.
PTC is a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. The company's strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders. To learn more about PTC, please visit www.ptcbio.com and follow us on LinkedIn, X, Instagram and Facebook.

For more information, please contact:

Investors:
Ellen Cavaleri
+1 (615) 618-8228
[email protected]

Media:
Jeanine Clemente
+1 (908) 912-9406
[email protected]

SOURCE PTC Therapeutics, Inc.

– First quarter 2026 total revenue of $273 million, including $226 million of product revenue, supporting full-year 2026 guidance raise –    – Global Sephience™ (sepiapterin) launch momentum continues with first quarter 2026 revenue of $125 million, representing 36% quarter-over-quarter growth – – Positive topline results from 24-month interim analysis of PIVOT-HD extension study of votoplam, supporting ongoing global Phase 3 INVEST-HD study and potential regulatory interactions – – Open-label vatiquinone registration study to be initiated in Q3 2026 based on FDA feedback – WARREN, N.J., May 7, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the first quarter ended March 31, 2026.

While the top- and bottom-line numbers for PTC Therapeutics (PTCT) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

MarketBeat Instant News Alerts Trending News All MarketBeat Instant News Alerts Sort By

Time Frame

Alert Type

Keywords

Page 1 of 324

Get 30 Days of MarketBeat All Access for Free

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools.

Start Your 30-Day Trial

Sign in to your free account to enjoy these benefits

In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer.

PTC Therapeutics, Inc. (PTCT) Presents at Bank of America Global Healthcare Conference 2026 Transcript